Recent Events - The approval of the generic drug Fumaric Acid Vonoprazan Tablets, originally developed by Takeda Pharmaceutical, is set for January 30, 2026, and is expected to prepare for market expansion after the patent expiration on August 29, 2026. Currently, 39 companies have been approved for this product, indicating potential price competition post-patent expiration [1] - The original drug's market share may decline rapidly after patent expiration, leading to significant downward pressure on generic drug prices, raising concerns about the long-term profitability of the company [1] Product Development Progress - The first innovative drug, Injection Imatinib, is expected to receive domestic approval by 2026, with three additional drugs recognized as breakthrough therapies anticipated to launch between 2027 and 2028 [2] - The BLA approval for Insulin Glargine in the U.S. market is expected to be completed in the first half of 2026, while Insulin Aspart is planned for approval by the end of 2026, aiding international expansion [2] - In January 2026, the SGLT-2 inhibitor Ologliptin Capsules were approved for market release, and the company has partnered with Crystal Technology to develop an AI drug research platform, which is expected to catalyze short-term growth [2] Business and Technical Development - In January 2026, the company launched an AI-driven research platform focused on the PROTAC mechanism, integrating clinical pipeline data, with the first AI-driven small molecule drug HEC169584 entering clinical Phase I [3] - The company is accelerating internationalization through overseas business development partnerships, such as a nearly $1 billion licensing agreement with UK-based Apollo for the HEC88473 project in November 2024 [4] Company Structure and Governance - In August 2025, the company completed its listing on the Hong Kong Stock Exchange through the absorption and merger of Dongyangguang Changjiang Pharmaceutical, achieving overall listing of its pharmaceutical assets [5] - The actual controller changed to Zhang Yushuang in December 2025, with market attention on how the new leadership will drive strategic transformation [6] Industry and Risk Analysis - The company has a high dependency on its core product, Oseltamivir Phosphate (Kewai), which accounted for over 60% of revenue in the first half of 2025, necessitating attention to single product risks and the impact of centralized procurement [7] - The sentiment in the biopharmaceutical sector has been weak recently, with the A-share biopharmaceutical index declining by 3.52% over the past 20 days, and southbound funds reducing holdings by 38,060 shares [8]